Advertisement

Neuropsychology Review

, Volume 17, Issue 1, pp 61–72 | Cite as

Pharmacologic Treatment of Attention-Deficit/Hyperactivity Disorder: Efficacy, Safety and Mechanisms of Action

  • Steven R. Pliszka
Original Paper

Abstract

Studies examining the efficacy, safety and mechanisms of action of agents for the treatment of attention-deficit/hyperactivity disorder (ADHD) are reviewed, with an emphasis on newer agents such as the long acting stimulants and atomoxetine. Recent studies of medications are characterized by large, rigorously diagnosed samples of children, adolescents and adults with ADHD, use of standardized rating scales and extensive safety data. These studies confirm a robust treatment effect for the Food and Drug Administration approved agents ranging from 0.7 to 1.5. The most common short term side effects to the most commonly used agents include insomnia, loss of appetite, and headaches. Despite public controversy and labeling changes to warn of extremely rare cardiovascular and psychiatric side effects, the evidence does not support the hypothesis that medication for ADHD increases risk for sudden death, mania or psychosis. A wide variety of neuroimaging techniques including electrocephalogram (EEG) power, event related potentials (ERP), functional magnetic resonance imaging (fMRI), and positron emission tomography (PET) are beginning to examine the mechanisms of action of medications for ADHD, and implicating the catecholamines and prefrontal and anterior cingulate cortices as prime sites of actions for these agents.

Keywords

ADHD Psychopharmacology Magnetic resonance imaging PET 

References

  1. Abikoff, H., McGough, J., Vitiello, B., McCracken, J., Davies, M., Walkup, J., et al. (2005). Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 418–427.PubMedCrossRefGoogle Scholar
  2. Allen, A. J., Kurlan, R. M., Gilbert, D. L., Coffey, B. J., Linder, S. L., Lewis, D. W., et al. (2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65, 1941–1949.PubMedCrossRefGoogle Scholar
  3. Aman, M. G., Binder, C., & Turgay, A. (2004). Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. Journal of Child and Adolescent Psychopharmacology, 14, 243–254.PubMedCrossRefGoogle Scholar
  4. Barkley, R. A. (1997). ADHD and the nature of self control. New York: Guildford Press.Google Scholar
  5. Barkley, R. A. (2006). Comorbid disorders, social and family adjustment, and subtyping. In R. A. Barkley (Ed.), Attention Deficit Hyperactivity Disorder (pp. 184–218). New York: Guilford Press.Google Scholar
  6. Barry, R. J., Clarke, A. R., & Johnstone, S. J. (2003). A review of electrophysiology in attention-deficit/hyperactivity disorder: I. Qualitative and quantitative electroencephalography. Clinical Neurophysiology, 114, 171–183.PubMedCrossRefGoogle Scholar
  7. Barry, R. J., Johnstone, S. J., & Clarke, A. R. (2003). A review of electrophysiology in attention-deficit/hyperactivity disorder: II. Event-related potentials. Clinical Neurophysiology, 114, 184–198.PubMedCrossRefGoogle Scholar
  8. Biederman, J., Lopez, F. A., Boellner, S. W., & Chandler, M. C. (2002). A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics, 110, 258–266.PubMedCrossRefGoogle Scholar
  9. Biederman, J., Mick, E., Surman, C., Doyle, R., Hammerness, P., Harpold, T., et al. (2006). A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 59, 829–835.PubMedCrossRefGoogle Scholar
  10. Biederman, J., Spencer, T. J., Wilens, T. E., Weisler, R. H., Read, S. C., & Tulloch, S. J. (2005). Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrum, 10, 16–25.Google Scholar
  11. Biederman, J., Wigal, S. B., Spencer, T. J., McGough, J. J., & Mays, D. A. (2006). A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clinical Therapeutics, 28, 280–293.PubMedCrossRefGoogle Scholar
  12. Bradley, C. (1937). The behavior of children receiving benzedrine. American Journal of Psychiatry, 94, 577–585.Google Scholar
  13. Broyd, S. J., Johnstone, S. J., Barry, R. J., Clarke, A. R., McCarthy, R., Selikowitz, M., et al. (2005). The effect of methylphenidate on response inhibition and the event-related potential of children with attention deficit/hyperactivity disorder. International Journal of Psychophysiology, 58, 47–58.PubMedCrossRefGoogle Scholar
  14. Bush, G. (2005). Funcitional MRI: Recent advances in studying ADHD pathophysiology and treatment. Presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, CA (Oct. 18–23).Google Scholar
  15. Bush, G., Frazier, J. A., Rauch, S. L., Seidman, L. J., Whalen, P. J., Jenike, M. A., et al. (1999). Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biological Psychiatry, 45, 1542–1552.PubMedCrossRefGoogle Scholar
  16. Bush, G., Valera, E. M., & Seidman, L. J. (2005). Functional neuroimaging of attention-deficit/hyperactivity disorder: A review and suggested future directions. Biological Psychiatry, 57, 1273–1284.PubMedCrossRefGoogle Scholar
  17. Castellanos, F. X. (2002). Proceed, with caution: SPECT cerebral blood flow studies of children and adolescents with attention deficit hyperactivity disorder. Journal of Nuclear Medicine, 43, 1630–1633.PubMedGoogle Scholar
  18. Charach, A., Figueroa, M., Chen, S., Ickowicz, A., & Schachar, R. (2006). Stimulant treatment over 5 years: Effects on growth. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 415–421.PubMedCrossRefGoogle Scholar
  19. Clarke, A. R., Barry, R. J., Bond, D., McCarthy, R., & Selikowitz, M. (2002). Effects of stimulant medications on the EEG of children with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl.), 164, 277–284.CrossRefGoogle Scholar
  20. Clarke, A. R., Barry, R. J., McCarthy, R., & Selikowitz, M. (2001). Electroencephalogram differences in two subtypes of attention-deficit/hyperactivity disorder. Psychophysiology, 38, 212–221.PubMedCrossRefGoogle Scholar
  21. Clarke, A. R., Barry, R. J., McCarthy, R., & Selikowitz, M. (2002). EEG differences between good and poor responders to methylphenidate and dexamphetamine in children with attention-deficit/hyperactivity disorder. Clinical Neurophysiology, 113, 194–205.PubMedCrossRefGoogle Scholar
  22. Conners, C. K., Casat, C. D., Gualtieri, C. T., Weller, E., Reader, M., Reiss, A., et al. (1996). Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1314–1321.PubMedCrossRefGoogle Scholar
  23. Connor, D. F., Fletcher, K. E., & Swanson, J. M. (1999). A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1551–1559.PubMedCrossRefGoogle Scholar
  24. Connor, D. F., Glatt, S. J., Lopez, I. D., Jackson, D., & Melloni, R. H., Jr. (2002). Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 253–261.PubMedCrossRefGoogle Scholar
  25. Correll, C. U. & Carlson, H. E. (2006). Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 771–791.PubMedGoogle Scholar
  26. Daly, J. M., & Wilens, T. (1998). The use of tricyclics antidepressants in children and adolescents. Pediatric Clinics of North America, 45, 1123–1135.PubMedCrossRefGoogle Scholar
  27. Faraone, S. V., Biederman, J., Morley, C. P., & Spencer, T. J. (2006). The effect of stimulants on height and weight: a review of the literature (manuscript in preparation).Google Scholar
  28. Feron, F. J., Hendriksen, J. G., van Kroonenburgh, M. J., Blom-Coenjaerts, C., Kessels, A. G., Jolles, J., et al. (2005). Dopamine transporter in attention-deficit hyperactivity disorder normalizes after cessation of methylphenidate. Pediatric Neurology, 33, 179–183.PubMedCrossRefGoogle Scholar
  29. Findling, R. L., & Lopez, F. A. (2005). Efficacy of transdermal methylphenidate with reference to Concerta in ADHD. Presented at the 25th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, CA, (Oct 18–23).Google Scholar
  30. Findling, R. L., Biederman, J., Wilens, T. E., Spencer, T. J., McGough, J. J., Lopez, F. A., et al. (2005). Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. The Journal of Pediatrics, 147, 348–354.PubMedCrossRefGoogle Scholar
  31. Food and Drug Administration (2005). FDA Alert [09/05]: Suicidal thinking in children and adolescents. Available at. Food and Drug Administration Website [On-line]. Available: http://www.fda.gov/cder/drug/infopage/atomoxetine/default.htmGoogle Scholar
  32. Gadow, K. D., Sverd, J., Sprafkin, J., Nolan, E. E., & Grossman, S. (1999). Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder [see comments]. Archives of General Psychiatry, 56, 330–336.PubMedCrossRefGoogle Scholar
  33. Gelperin, K. (2006). Psychiatric adverse events associated with drug treatment of ADHD: Review of post marketing safety data. Available at. Food and Drug Administration Website [On-line]. Available: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210B-Index.htmGoogle Scholar
  34. Greenhill, L. L., Biederman, J., Boellner, S. W., Rugino, T. A., Sangal, R. B., Earl, C. Q., et al. (2006a). A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 503–511.PubMedCrossRefGoogle Scholar
  35. Greenhill, L. L., Findling, R. L., & Swanson, J. M. (2002). A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 109, E39.PubMedCrossRefGoogle Scholar
  36. Greenhill, L. L., Muniz, R., Ball, R. R., Levine, A., Pestreich, L., & Jiang, H. (2006b). Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 817–823.PubMedCrossRefGoogle Scholar
  37. Hammad, T. A., Laughren, T., & Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63, 332–339.PubMedCrossRefGoogle Scholar
  38. Jensen, P. S., Youngstrom, Y., Steiner, H., Findling, R. L., Meyer, R. E., Malone, R., et al. (in press) Consensus report: Impulsive aggression as a symptom across diagnostic categories in child psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry.Google Scholar
  39. Jonkman, L. M., Kemner, C., Verbaten, M. N., van Engeland, H., Camfferman, G., Buitelaar, J. K., et al. (2000). Attentional capacity, a probe ERP study: Differences between children with attention-deficit hyperactivity disorder and normal control children and effects of methylphenidate. Psychophysiology, 37, 334–346.PubMedCrossRefGoogle Scholar
  40. Jucaite, A., Fernell, E., Halldin, C., Forssberg, H., & Farde, L. (2005). Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity. Biological Psychiatry, 57, 229–238.PubMedCrossRefGoogle Scholar
  41. Kim, B. N., Lee, J. S., Cho, S. C., & Lee, D. S. (2001). Methylphenidate increased regional cerebral blood flow in subjects with attention deficit/hyperactivity disorder. Yonsei Medical Journal, 42, 19–29.PubMedGoogle Scholar
  42. Klein, R. G., Abikoff, H., Klass, E., Ganeles, D., Seese, L. M., & Pollack, S. (1997). Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Archives of General Psychiatry, 54, 1073–1080.PubMedGoogle Scholar
  43. Klorman, R. (1991). Cognitive event-related potentials in attention deficit disorder. Journal of Learning Disabilities, 24, 130–140.PubMedCrossRefGoogle Scholar
  44. Kok, A. (1986). Effects of degradation of visual stimuli on components of the event-related potential (ERP) in go/nogo reaction tasks. Biological Psychology, 23, 21–38.PubMedCrossRefGoogle Scholar
  45. Kok, A. (1997). Event-related-potential (ERP) reflections of mental resources: A review and synthesis. Biological Psychology, 45, 19–56.PubMedCrossRefGoogle Scholar
  46. Krause, K. H., Dresel, S. H., Krause, J., la Fougere, C., & Ackenheil, M. (2003). The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neuroscience and Biobehavioral Reviews, 27, 605–613.PubMedCrossRefGoogle Scholar
  47. Langleben, D. D., Acton, P. D., Austin, G., Elman, I., Krikorian, G., Monterosso, J. R., et al. (2002). Effects of methylphenidate discontinuation on cerebral blood flow in prepubescent boys with attention deficit hyperactivity disorder. Journal of Nuclear Medicine, 43, 1624–1629.PubMedGoogle Scholar
  48. Loo, S. K. & Barkley, R. A. (2005). Clinical utility of EEG in attention deficit hyperactivity disorder. Applied Neuropsychology, 12, 64–76.PubMedCrossRefGoogle Scholar
  49. Loo, S. K., Hopfer, C., Teale, P. D., & Reite, M. L. (2004). EEG correlates of methylphenidate response in ADHD: Association with cognitive and behavioral measures. Journal of Clinical Neurophysiology, 21, 457–464.PubMedCrossRefGoogle Scholar
  50. Loo, S. K., Specter, E., Smolen, A., Hopfer, C., Teale, P. D., & Reite, M. L. (2003). Functional effects of the DAT1 polymorphism on EEG measures in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 986–993.PubMedCrossRefGoogle Scholar
  51. Matochik, J. A., Liebenauer, L. L., King, A. C., Szymanski, H. V., Cohen, R. M., & Zametkin, A. J. (1994). Cerebral glucose metabolism in adults with attention deficit hyperactivity disorder after chronic stimulant treatment. American Journal of Psychiatry, 151, 658–664.PubMedGoogle Scholar
  52. Matochik, J. A., Nordahl, T. E., Gross, M., Semple, W. E., King, A. C., Cohen, R. M., et al. (1993). Effects of acute stimulant medication on cerebral metabolism in adults with hyperactivity. Neuropsychopharmacology, 8, 377–386.PubMedGoogle Scholar
  53. McGough, J. J., Biederman, J., Wigal, S. B., Lopez, F. A., McCracken, J. T., Spencer, T., et al. (2005). Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 530–538.PubMedCrossRefGoogle Scholar
  54. Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., et al. (2003). Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biological Psychiatry, 53, 112–120.PubMedCrossRefGoogle Scholar
  55. Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., et al. (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896–1901.PubMedCrossRefGoogle Scholar
  56. Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, R., et al. (2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics, 108, 1–9.CrossRefGoogle Scholar
  57. MTA Cooperative Group (2004). National institute of mental health multimodal treatment study of ADHD follow-up: Changes in effectiveness and growth after the end of treatment. Pediatrics, 113, 762–769.CrossRefGoogle Scholar
  58. MTA Cooperative Group (2006). Effects of stimulant medication on growth rates across three years in the MTA follow up. (in submission).Google Scholar
  59. Muller, U., Clark, L., Lam, M. L., Moore, R. M., Murphy, C. L., Richmond, N. K., et al. (2005). Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology (Berl.), 182, 205–213.CrossRefGoogle Scholar
  60. Newcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D. (2005). Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 240–248.PubMedCrossRefGoogle Scholar
  61. Pappadopulos, E., Macintyre Ii, J. C., Crismon, M. L., Findling, R. L., Malone, R. P., Derivan, A., et al. (2003). Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 145–161.PubMedCrossRefGoogle Scholar
  62. Pliszka, S. R., Browne, R., Olvera, R. L., & Wynne, S. K. (2000). A double-blind placebo controlled trial of Adderall and methylphendiate in the treatment of Attention deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 619–626.PubMedCrossRefGoogle Scholar
  63. Pliszka, S. R., Crismon, M. L., Hughes, C. W., Corners, C. K., Emslie, G. J., Jensen, P. S., et al. (2006a). The Texas Children’s Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 642–657.PubMedCrossRefGoogle Scholar
  64. Pliszka, S. R., Glahn, D. C., Semrud-Clikeman, M., Franklin, C., Perez, R., Xiong, J., et al. (2006b). Neuroimaging of inhibitory control areas in children with attention defict hyperactivity disorder who were treatment naive or in long term treatment. American Journal of Psychiatry, 163, 1052–1060.PubMedCrossRefGoogle Scholar
  65. Pliszka, S. R., Liotti, M., & Woldorff, M. G. (2000). Inhibitory control in children with attention deficit/hyperactivity disorder: Event related potentials identify the processing component and timing of an impaired right-frontal response-inhibition mechanism. Biological Psychiatry, 48, 238–246.PubMedCrossRefGoogle Scholar
  66. Pliszka, S. R., Matthews, T. L., Braslow, K. J., & Watson, M. A. (2006c). Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder (ADHD). Journal of the American Academy of Child and Adolescent Psychiatry, 45, 520–526.PubMedCrossRefGoogle Scholar
  67. Poulton, A. (2005). Growth on stimulant medication; clarifying the confusion: A review. Archives of Diseases of Childhood, 90, 801–806.CrossRefGoogle Scholar
  68. Rosa-Neto, P., Lou, H. C., Cumming, P., Pryds, O., Karrebaek, H., Lunding, J., et al. (2005). Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage, 25, 868–876.PubMedCrossRefGoogle Scholar
  69. Rubia, K., Smith, A. B., Brammer, M. J., Toone, B., & Taylor, E. (2005). Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. American Journal of Psychiatry, 162, 1067–1075.PubMedCrossRefGoogle Scholar
  70. Scahill, L., Chappell, P. B., Kim, Y. S., Schultz, R. T., Katsovich, L., Shepherd, E., et al. (2001). A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry, 158, 1067–1074.PubMedCrossRefGoogle Scholar
  71. Schmajuk, M., Liotti, M., Busse, L., & Woldorff, M. G. (2006). Electrophysiological activity underlying inhibitory control processes in normal adults. Neuropsychologia., 44, 384–395.PubMedCrossRefGoogle Scholar
  72. Schur, S. B., Sikich, L., Findling, R. L., Malone, R. P., Crismon, M. L., Derivan, A., et al. (2003). Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: A review. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 132–144.PubMedCrossRefGoogle Scholar
  73. Schweitzer, J. B., Lee, D. O., Hanford, R. B., Tagamets, M. A., Hoffman, J. M., Grafton, S. T., et al. (2003). A positron emission tomography study of methylphenidate in adults with ADHD: Alterations in resting blood flow and predicting treatment response. Neuropsychopharmacology, 28, 967–973.PubMedGoogle Scholar
  74. Seifert, J., Scheuerpflug, P., Zillessen, K. E., Fallgatter, A., & Warnke, A. (2003). Electrophysiological investigation of the effectiveness of methylphenidate in children with and without ADHD. Journal of Neural Transmission, 110, 821–829.PubMedGoogle Scholar
  75. Shafritz, K. M., Marchione, K. E., Gore, J. C., Shaywitz, S. E., & Shaywitz, B. A. (2004). The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. American Journal of Psychiatry, 161, 1990–1997.PubMedCrossRefGoogle Scholar
  76. Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., & Carroll, A. (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1026–1036.PubMedCrossRefGoogle Scholar
  77. Spencer, T., Biederman, J., Wilens, T., Harding, M., O’Donnell, D., & Griffin, S. (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 409–432.PubMedCrossRefGoogle Scholar
  78. Spencer, T. J., Biederman, J., Madras, B. K., Faraone, S. V., Dougherty, D. D., Bonab, A. A., et al. (2005). In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: A focus on the dopamine transporter. Biological Psychiatry, 57, 1293–1300.PubMedCrossRefGoogle Scholar
  79. Spencer, T. J., Faraone, S. V., Biederman, J., Lerner, M., Cooper, K. M., & Zimmerman, B. (2006a). Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? Journal of the American Academy of Child and Adolescent Psychiatry, 45, 527–537.PubMedCrossRefGoogle Scholar
  80. Spencer, T. J., Wilens, T. E., Biederman, J., Weisler, R. H., Read, S. C., & Pratt, R. (2006b). Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: A 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics, 28, 266–279.PubMedCrossRefGoogle Scholar
  81. Sumner, C. S., Donnelly, C., Lopez, F. A., Sutton, V., Bakken, R., Paczkowski, M., et al. (2005). Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety. Presented at the annual meeting of the American Psychiatric Association, Altanta, GA (May).Google Scholar
  82. Swanson, J. M., Greenhill, L. L., Lopez, F. A., Sedillo, A., Earl, C. Q., Jiang, J. G., et al. (2006). Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. Journal of Clinical Psychiatry, 67, 137–147.PubMedCrossRefGoogle Scholar
  83. Swanson, J. M., McBurnett, K., Wigal, T., Pfiffner, L. J., Lerner, M. A., Williams, L., et al. (1993). Effect of stimulant medication on children with attention deficit disorder: A “review of reviews.”Exceptional Children, 60, 154–162.Google Scholar
  84. Swensen, A., Michelsen, D., Buesching, D., & Faries, D. E. (2001). Effects of atomoxetine on social and family functioning of ADHD children and adolescents. Presented at the 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu,HI, (Oct 23–28).Google Scholar
  85. Szobot, C. M., Ketzer, C., Cunha, R. D., Parente, M. A., Langleben, D. D., Acton, P. D., et al. (2003). The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder. European Journal of Nuclear Medicine and Molecular Imaging, 30, 423–426.PubMedCrossRefGoogle Scholar
  86. Tourette’s Syndrome Study Group (2002). Treatment of ADHD in children with tics: A randomized controlled trial. Neurology, 58, 527–536.Google Scholar
  87. Vaidya, C. J., Austin, G., Kirkorian, G., Ridlehuber, H. W., Desmond, J. E., Glover, G. H., et al. (1998). Selective effects of methylphenidate in attention deficit hyperactivity disorder: A functional magnetic resonance study. Proceedings of the National Academy of Science, 95, 14494–14499.CrossRefGoogle Scholar
  88. Villalaba, L. (2006). Follow up review of AERS search identifying cases of sudden death occuring with drugs used for the treatment of attention deficit hyperactivity disorder (ADHD). Available at. Food and Drug Administration Website [On-line]. Available: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210B-Index.htmGoogle Scholar
  89. Vles, J. S., Feron, F. J., Hendriksen, J. G., Jolles, J., van Kroonenburgh, M. J., & Weber, W. E. (2003). Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics., 34, 77–80.PubMedCrossRefGoogle Scholar
  90. Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Gerasimov, M., Maynard, L., et al. (2001). Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. Journal of Neuroscience, 21, RC121.PubMedGoogle Scholar
  91. Volkow, N. D., Wang, G. J., Fowler, J. S., & Ding, Y. S. (2005). Imaging the effects of methylphenidate on brain dopamine: New model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biological Psychiatry, 57, 1410–1415.PubMedCrossRefGoogle Scholar
  92. Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., et al. (1998). Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry, 155, 1325–1331.PubMedGoogle Scholar
  93. Volkow, N. D., Wang, G. J., Fowler, J. S., Telang, F., Maynard, L., Logan, J., et al. (2004). Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. American Journal of Psychiatry, 161, 1173–1180.PubMedCrossRefGoogle Scholar
  94. Weisler, R. H., Biederman, J., Spencer, T. J., Wilens, T. E., Faraone, S. V., Chrisman, A. K., et al. (2006). Mixed amphetamine salts extended-release in the treatment of adult ADHD: A randomized, controlled trial. CNS Spectrum, 11, 625–639.Google Scholar
  95. Weiss, M., Wasdell, M., & Patin, J. (2004). A post hoc analysis of d-threo-methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin). Journal of the American Academy of Child and Adolescent Psychiatry, 43, 1415–1421.PubMedCrossRefGoogle Scholar
  96. Wigal, S. B., McGough, J. J., McCracken, J. T., Biederman, J., Spencer, T. J., Posner, K. L., et al. (2005). A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. Journal of Attention Disorders, 9, 275–289.PubMedCrossRefGoogle Scholar
  97. Wilens, T., McBurnett, K., Stein, M., Lerner, M., Spencer, T., & Wolraich, M. (2005). ADHD treatment with once daily OROS methylphendiate treatment: Final results from a long term open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 1015–1023.PubMedCrossRefGoogle Scholar
  98. Wilens, T. E., McBurnett, K., Bukstein, O., McGough, J., Greenhill, L., Lerner, M., et al. (2006). Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine, 160, 82–90.PubMedCrossRefGoogle Scholar
  99. Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., et al. (2001). Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics, 108, 883–892.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Division of Child and Adolescent PsychiatryDepartment of PsychiatrySan AntonioUSA

Personalised recommendations